

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/VAB0EF67474EN.html>

Date: April 2018

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: VAB0EF67474EN

Abstracts

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

SUMMARY

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Nephropathy, Diabetic Retinopathy, Choroidal Neovascularization, Lipid Disorders, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion and Retinopathy.

The latest report Vascular Endothelial Growth Factor B - Pipeline Review, H1 2018, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects

The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies
Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

CSL Ltd

Eli Lilly and Co

Formycon AG

Momenta Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones

Featured News & Press Releases

Mar 20, 2018: Aflibercept shows promising data for non-proliferative DR

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)

Dec 21, 2017: Bayer Yakuhin Announces Results on EYLEA at the 11th Asia Pacific Retinal Vitreological Society (APVRS)

Dec 11, 2017: Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD

Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program

Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV

Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017

Jul 10, 2017: New use of drug could reduce need for laser treatment in diabetes

May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017

Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease

Feb 02, 2017: Benitec Biopharma makes significant progress in ocular program

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Alteogen Inc, H1 2018

Pipeline by Benitec Biopharma Ltd, H1 2018

Pipeline by CSL Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Formycon AG, H1 2018

Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd.1), H1 2018

Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Alteogen Inc

Benitec Biopharma Ltd

CSL Ltd

Eli Lilly and Co

Formycon AG

Momenta Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

I would like to order

Product name: Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/VAB0EF67474EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VAB0EF67474EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

